Clinical

Compared with chemotherapy, patients receiving avelumab or another immunotherapy had higher response rates and higher rates of survival in locally advanced Merkel cell carcinoma (laMCC) and metastatic Merkel cell carcinoma (mMCC).

Dynamic measurable residual disease (MRD) can be used to optimize postremission treatment for young patients with acute myeloid leukemia (AML).

The gold standard for diagnosing liver disease is a liver biopsy, but researchers are seeking a simpler way to identify those at risk, given the silent nature of early disease and rising incidence around the globe.

Across 19 patients, 73% developed grade 3 or 4 neutropenia, significantly higher than the incidence observed in the phase 3 trial examining the combination for chronic lymphocytic leukemia (CLL).

A study abstract presented at the European Hematology Association annual meeting found that, in a real-world setting, ruxolitinib resulted in prolonged survival among patients receiving the treatment following an allogeneic hematopoietic cell transplant.

The manipulation of key enzymes through methods of gene therapy was shown to provide protection against vision loss from multiple retinal conditions.

Inconsistent application and measure of the Kidney Disease Improving Global Outcomes definition of acute kidney injury (AKI) prompted this review, which used a measure of 75% agreement when defining consensus.

In this retrospective cohort study of patients with newly diagnosed psoriatic arthritis, the authors examine the association of treatment selection and costs with physician specialty.

This new study from Japan investigated possible relationships between tubular injury, COVID-19 severity, and inflammatory markers with development of acute kidney injury.

The researchers identified 3 immune subtypes of esophageal cancer (EC) among the samples, all of which had different prognostic implications.

Early assessment of risks for other disorders may significantly improve long-term outcomes.

A new treatment using human immune cells can prevent infections in patients with leukemia who have a weakened immune system due to treatment for their disease.

A survey of global physicians found a gap in knowledge of non-alcoholic fatty liver disease (NAFLD) despite the growing burden of the disease worldwide.

The nationwide, population-based study analyzed data on over 1900 patients with primary myelofibrosis (pMF), comparing rates of survival from 2001-2010 with 2011-2018.

Different ulcer wound treatments were analyzed in elderly patients with multiple medical conditions, revealing that a multidisciplinary approach may be needed to ensure efficacy.

A database of information about more than 30,000 patients verified improved morbidity and mortality due to vaccines and preventive health care in prospective trials.

The more often a patient used systemic corticosteroids, the higher their risk of moderate or severe COVID-19 and all-cause mortality, the study found.

Based on subgroup analyses of over 500 younger patients with intermediate-risk disease, the researchers say measurable residual disease (MRD)-guided decisions may help achieve better outcomes postremission.

Based on difference-in-difference (DID) analysis, genomics-informed treatment increased time to treatment discontinuation by an estimated 3 months and increased costs by an estimated C$90,000—equivalent to approximately US$72,000—compared with standard care treatment.

No clinical or genetic markers were found to be predictive of psoriatic arthritis in patients with psoriasis, but one laboratory marker was identified.

In part 7 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed telehealth and the role of remote care.

In part 6 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed examples of game-changing therapy in cancer care.

In part 5 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed why AccessHope offers an option to payers and oncologists.

In part 4 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed how the therapeutic pipeline has changed.

In part 3 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed the payer perspective in the rise of genomics.